Company news
Oncolys BioPharma, Inc. news in 2021
Oncolys BioPharma, Inc.'s news releases, calls and decks from 2021, newest first.
First Patient Dosed in NRG Oncology Phase I Clinical Trial for Telomelysin(OBP-301)-Chemoradiation Combination Therapy for Esophageal Cancer Patients
December 7, 2021
Announcement of Enrollment of First Patient in Phase IIa Clinical Trial of OBP-601 (Censavudine, TPN-101) in Patients with PSP
November 18, 2021
Non-consolidated Financial Results for the Nine Months Ended September 30, 2021 [Japanese GAAP]
November 5, 2021
Announcement of FDA Clearance of Two IND Applications to Initiate Phase 2 Clinical Trials of OBP-601 (Censavudine, TPN-101)
August 15, 2021
Oncolys BioPharma to partner with Thermo Fisher Scientific for viral vector development and GMP manufacturing of their proprietary oncolytic virus, OBP-301
August 4, 2021